MTOR and breast carcinoma: It can activate multiple pathways, including the JAK/STAT3 and the AKT/mTOR pathways, and is frequently overexpressed in breast cancer and other tumour types, playing a role in promoting tumour progression, metastasis and EMT phenotype [70,71].